This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.
The two companies are already working together on RNAi drugs against hepatitis B virus.
Alnylam has claimed European Commission approval for its second RNA interface (RNAi) drug Givlaari for acute hepatic porphyria. ... Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar
Leading the flurry of recommendations was Givlaari (givosiran), Alnylam’s second RNAi drug, for acute hepatic porphyria.
RNA interference (RNAi) drug lumasiran works upstream of the deficient enzyme, switching off production of a substrate that it converts to oxalate. ... If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for
This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)
Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari. ... RNAi drugs work by switching off genes that aren’t working properly, and Givlaari is only the
More from news
Approximately 10 fully matching, plus 41 partially matching documents found.
With the introduction of new data analytics capabilities and broader adoption in the pharmaceutical industry, research platforms that heavily depend on data (eg, RNAi and CRISPR therapies) will likely increase their
More than a decade of research into its RNA interference (RNAi) drugs generated the first ever approval of a drug in this category towards the end of 2018, and the company ... 2020 will be a big year as it continues its transformation into a
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
This has been Alnylam’s story over the past 16 years, as it built on Andrew Fire and Craig Mello’s Nobel prize winning discovery that naturally occurring RNAi “silences” genes, ... Its RNAi technology can be used to target any gene expressed in
New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...